Thus our results and the above-described literature [57–61] emphasize the interest of further investigating the effects of RSK3 inhibition in different type of cancers, alone, at least in claudin-low breast tumors, or in combination with drugs targeting pro-tumoral pathways, for many types of tumors. The gene discussed is RPS6KA2; the disease is cancer.